机构：[1]Laboratory of Molecular Translational Medicine, West China Institute of Women and Children’s Health, Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, China[2]Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[3]Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China[4]Department of Forensic Biology, West China School of Preclinical and ForensicMedicine, Sichuan University, Chengdu 610041, China[5]Department of Urology, Institute of Oncology, the Second People’s Hospital of Sichuan, Chengdu, China
Programmed cell death 6 (PDCD6) has recently been found dysregulated in tumors of various origin. The aim of this study is to explore the association between PDCD6 genetic polymorphisms and susceptibility to bladder cancer and survival of patients with bladder cancer. Two tag SNPs of PDCD6, rs3756712 and rs4957014, were genotyped in 332 patients with bladder cancer and 509 controls by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method and correlated with patients' survival. The frequencies of G allele and GG genotype of rs3756712 in patients were significantly lower than that of controls (P = 0.001, odds ratio [OR] = 0.68 for G allele; P = 0.024, OR = 0.53 for GG genotype in the recessive genetic model, respectively). The GT genotype of rs4957014 was associated with decreased susceptibility to bladder cancer in the overdominant genetic model (P = 0.023, OR = 0.72). Kaplan-Meier curves revealed a significant higher risk for death in superficial bladder cancer patients harboring GG homozygous of rs3756712 (P < 0.001), and an increased risk for recurrence in invasive bladder cancer patients carrying GT heterozygous of rs4957014 (P = 0.04). Multiple Cox regression analysis identified rs3756712 GG genotype as an independent prognostic factor for death in superficial bladder cancer patients (hazard ratio [HR] = 5.11, P = 0.01), and rs4957014 GT genotype as an independent prognostic factor for recurrence in invasive bladder cancer patients (HR = 1.93, P = 0.03). PDCD6 may represent a biomarker candidate gene that could help to identify a group of patients at high risk for recurrence and death.
基金：
National Natural
Science Foundation of China (No. 81172494, No. 81172440, No.
81272821 and No. 81202023); the Applied Basic Research Programs
of Science and Technology Commission Foundation of Sichuan Province
(No. 2012SZ0008); and the Science Foundation for The Excellent Youth
Scholars of Sichuan University (No. 2011SCU04A16).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2014]版：
大类|3 区医学
小类|4 区肿瘤学
最新[2023]版：
无
第一作者：
第一作者机构：[1]Laboratory of Molecular Translational Medicine, West China Institute of Women and Children’s Health, Key Laboratory of Obstetric and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhou Bin,Zhang Peng,Tang Tielong,et al.Prognostic value of PDCD6 polymorphisms and the susceptibility to bladder cancer.[J].Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.2014,35(8):7547-54.doi:10.1007/s13277-014-2010-1.
APA：
Zhou Bin,Zhang Peng,Tang Tielong,Zhang Kui,Wang Yanyun...&Zhang Lin.(2014).Prognostic value of PDCD6 polymorphisms and the susceptibility to bladder cancer..Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,35,(8)
MLA：
Zhou Bin,et al."Prognostic value of PDCD6 polymorphisms and the susceptibility to bladder cancer.".Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 35..8(2014):7547-54
